MedWatch

Sydbank: A positive signal

Sydbank analyst, Søren Løntoft Hansen, is up-beat about the expected, European sales-level of Lundbeck’s new pill for alcohol addiction, albeit less so than the company itself.

Foto: Sydbank/PR

EU approval of the Danish company’s alcohol-pill, Selincro, would send a great signal, as the company would gain be gaining approval for drugs that can help it traverse an impending patent cliff, says Sydbank’s stock market analyst and pharmaceutical expert, Søren Løntoft Hansen. But he is not quite as positive as Lundbeck when it comes to expectations for annual European sales.

“Lundbeck expects a top sales potential of 2.5 billion kroner (442 million USD). My estimate is somewhat lower, and I think the same goes for my colleagues. We want to wait and see how sales develop. My top sales estimate is at 1.4 billion kroner (247 million USD). But you can safely say that the pill has a potential of more than a billion,” he tells Medwatch.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier